Deborah Autor Sells 34,819 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Deborah Autor sold 34,819 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Amneal Pharmaceuticals Trading Down 1.4%

AMRX traded down $0.18 during trading on Tuesday, hitting $12.60. The stock had a trading volume of 1,227,129 shares, compared to its average volume of 2,288,625. The firm has a market cap of $3.96 billion, a PE ratio of 33.16 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a 12 month low of $7.02 and a 12 month high of $15.42. The company has a 50 day simple moving average of $12.76 and a 200-day simple moving average of $12.77.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The firm had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 272.31%. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at $26,000. Federated Hermes Inc. raised its stake in shares of Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after buying an additional 2,168 shares in the last quarter. Spire Wealth Management raised its stake in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after buying an additional 1,023 shares in the last quarter. Transamerica Financial Advisors LLC raised its stake in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after buying an additional 2,460 shares in the last quarter. Finally, Comerica Bank raised its stake in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. UBS Group assumed coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 target price for the company. Truist Financial upped their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.